Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ashley Matusz-Fisher & Antoinette R. Tan. (2022) Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. Expert Opinion on Biological Therapy 22:3, pages 385-395.
Read now
Read now
Megan Jagosky & Antoinette R Tan. (2021) Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer: Targets and Therapy 13, pages 393-407.
Read now
Read now
David D Stenehjem, Minkyoung Yoo, Sudhir K Unni, Mukul Singhal, Hillevi Bauer, Kim Saverno, Cheng Quah, Anthony Masaquel & Diana I Brixner. (2014) Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Breast Cancer: Targets and Therapy 6, pages 169-177.
Read now
Read now
Eman El-Abd, Cecil A. Matta, Manal Sheta, Yasser El-Kerm & Shimaa Sakr. (2014) Histopathological characteristics of breast cancer and evaluation of ER alpha and Her-2neu using immunohistochemical and RT-PCR techniques. Alexandria Journal of Medicine 50:3, pages 275-282.
Read now
Read now
Ewa Mrózek, Stephen P Povoski & Charles L Shapiro. (2013) The challenges of individualized care for older patients with localized breast cancer. Expert Review of Anticancer Therapy 13:8, pages 963-973.
Read now
Read now
Asmaa Al-Allak, Paul D Lewis & Gianfilippo Bertelli. (2012) Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review. Expert Review of Anticancer Therapy 12:8, pages 1033-1043.
Read now
Read now
Articles from other publishers (93)
Yuanke Liang, Jinxing Liu, Cong Zhao, Hexing Sun, Kaiyuan Huang, Qin Xie, De Zeng, Haoyu Lin & Benqing Zhou. (2023) HER2-targeting two-dimensional black phosphorus as a nanoplatform for chemo-photothermal therapy in breast cancer. Materials Today Bio 23, pages 100812.
Crossref
Crossref
Guido Giordano, Gaia Griguolo, Matteo Landriscina, Icro Meattini, Francesco Carbone, Augusto Leone, Marzia Del Re, Stefano Fogli, Romano Danesi, Antonio Colamaria & Maria Vittoria Dieci. (2023) Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data. Critical Reviews in Oncology/Hematology 192, pages 104185.
Crossref
Crossref
Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé & Agnès Leroux. (2023) Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS). Biomedicines 11:12, pages 3164.
Crossref
Crossref
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, Mika K. Kaneko & Yukinari Kato. (2023)
Antitumor activities against breast cancers by an afucosylated
anti‐HER2
monoclonal antibody
H
2
Mab‐77‐mG
2a
‐f
. Cancer Science.
Crossref
Crossref
T. I. Deshkina, L. V. Bolotina, P. V. Golubev, I. E. Gabuniya, M. S. Ruban, A. A. Fedenko & A. D. Kaprin. (2023) De-escalation of neoadjuvant therapy as an option for patients with HER2 positive breast cancer. Malignant tumours 13:3, pages 29-36.
Crossref
Crossref
Gary Tozbikian. (2023) The Significance of Recognition of Human Epidermal Growth Factor 2 Low in Breast Cancer Therapy. Advances in Anatomic Pathology 30:6, pages 388-396.
Crossref
Crossref
Yuxin Mu, Yanchun Meng, Yiqun Du, Xiaojun Liu & Jian Zhang. (2023)
Clinical characteristics and treatment outcomes of
HER2
mutation and
HER2
fusion in 22 patients with advanced breast cancer
. Thoracic Cancer.
Crossref
Crossref
Raza Abbas Syed, Matthew G. Davey, Vinitha Richard, Nicola Miller & Michael J. Kerin. (2023) Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer. International Journal of Molecular Sciences 24:16, pages 12694.
Crossref
Crossref
Kovilen Sawmynaden, Nicholas Wong, Sarah Davies, Richard Cowan, Richard Brown, David Tang, Maud Henry, David Tickle, David Matthews, Mark Carr, Preeti Bakrania, Hong Hoi Ting & Gareth Hall. (2023) Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool. PLOS ONE 18:7, pages e0288259.
Crossref
Crossref
Arya Mariam Roy, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal, Ruth O’Regan & Shipra Gandhi. (2023) A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer.
Crossref
Crossref
Monika Iwasaki, Clara So & Torahiko Jinta. (2023) Identification of a TP53 Mutation in a Patient With Li-Fraumeni Syndrome and Not Meeting the Revised Chompret Criteria: A Case Report. Cureus.
Crossref
Crossref
Tianli Hui, Sainan Li, Huimin Wang, Xuejiao Ma, Furong Du, Wei Gao, Shan Yang, Meixiang Sang, Ziyi Li, Ran Ding, Yueping Liu & Cuizhi Geng. (2023) An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer. The Oncologist.
Crossref
Crossref
Yanjun Hou, Hiroaki Nitta & Zaibo Li. (2023) HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers 15:10, pages 2664.
Crossref
Crossref
Stephanie L. Graff, Fengting Yan & Yara Abdou. (2023) Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer.
Crossref
Crossref
Fan Wang, Linghui Fang, Bifei Fu & Chen Fan. (2023) Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes. Breast Cancer 30:3, pages 478-488.
Crossref
Crossref
Olga Martínez-Sáez & Adrienne G. Waks. (2023) Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer. Current Treatment Options in Oncology 24:5, pages 479-495.
Crossref
Crossref
Volkmar Müller, Rupert Bartsch, Nancy U. Lin, Filippo Montemurro, Mark D. Pegram & Sara M. Tolaney. (2023) Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treatment Reviews 115, pages 102527.
Crossref
Crossref
Chang-Gen Liu, Yi-Fan Li, Tian-Yi Ma, Meng Lv, Zhi-Dong Lv, Yuan-Yuan Wang, Xiang-Ping Liu, Yan Mao & Hai-Bo Wang. (2023) Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study. Frontiers in Oncology 13.
Crossref
Crossref
Qiongwen Zhang, Ping He, Tinglun Tian, Xi Yan, Juan Huang, Zhang Zhang, Hong Zheng, Xiaorong Zhong & Ting Luo. (2023) Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study. Frontiers in Pharmacology 14.
Crossref
Crossref
Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Gerardo Miceli Sopo, Giampiero Mazzaglia, Pierfranco Conte & Lorenzo Giovanni Mantovani. (2023) The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis. Cancers 15:4, pages 1175.
Crossref
Crossref
Leah H. Portnow, Jeanne M. Kochkodan-SelfAmy MaduramMirelys Barrios, Allison M. OnkenXuefei HongElizabeth A. MittendorfCatherine S. Giess & Sona A. Chikarmane. (2023) Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. RadioGraphics 43:2.
Crossref
Crossref
Aolei Chen, Shaotang Ye, Jiahui Zheng, Jichao Li, Zejia Chen, Yashan Zhang & Shoujun Li. (2023) Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line. BMC Veterinary Research 19:1.
Crossref
Crossref
Charlie Yang, Christine Brezden-Masley, Anil Abraham Joy, Sandeep Sehdev, Shanu Modi, Christine Simmons & Jan-Willem Henning. (2023) Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Therapeutic Advances in Medical Oncology 15, pages 175883592311754.
Crossref
Crossref
Lingfeng Tang, Zhenghang Li, Linshan Jiang, Xiujie Shu, Yingkun Xu & Shengchun Liu. (2022) Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. Frontiers in Oncology 12.
Crossref
Crossref
Zaid Sirhan, Anita Thyagarajan & Ravi P. Sahu. (2022) The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Medical Research 9:1.
Crossref
Crossref
Nathaniel Hendrix, Nina Oestreicher, Deepa Lalla, Chantal M. Dolan, Kathryn A. Fisher, David L. Veenstra & Beverly Moy. (2022) Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer 22:8, pages 781-791.
Crossref
Crossref
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann & Khalil Zaman. (2022) Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. The Breast 66, pages 145-156.
Crossref
Crossref
Xuelin Xia, Xiaoyuan Yang, Wei Huang, Xiaoxia Xia & Deyue Yan. (2021) Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers. Nano-Micro Letters 14:1.
Crossref
Crossref
Julie A Meyer, Sharon DeChenne, Charles A Foerder & Shawna M Hengel. (2022) Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis. Bioanalysis 14:22, pages 1443-1452.
Crossref
Crossref
Rui Han, Hongxing Yang, Changquan Ling & Lingeng Lu. (2022) Neurospora crassa is a potential source of anti-cancer agents against breast cancer. Breast Cancer 29:6, pages 1032-1041.
Crossref
Crossref
Niamh Cunningham, Scott Shepherd, Kabir Mohammed, Karla A. Lee, Mark Allen, Stephen Johnston, Emma Kipps, Sophie McGrath, Jillian Noble, Marina Parton, Alistair Ring, Nicholas C. Turner & Alicia F. C. Okines. (2022) Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital. Breast Cancer Research and Treatment 195:3, pages 333-340.
Crossref
Crossref
Jing Li, Jun Jiang, Xun Bao, Vineet Kumar, Stephen C. Alley, Scott Peterson & Anthony J. Lee. (2022) Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases. Clinical Cancer Research 28:15, pages 3329-3341.
Crossref
Crossref
Angelica Ferrando-Díez, Eudald Felip, Anna Pous, Milana Bergamino Sirven & Mireia Margelí. (2022) Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 14:14, pages 3305.
Crossref
Crossref
Xin-yang Li, Xin-hua Qian, Ju Zhu, Yu-heng Li, Qi-qi Lin, Shuai Li, Wen-han Xue, Ling-yan Jian & Fan-hao Meng. (2022) Synthesis and evaluation of novel HER-2 inhibitors to exert anti-breast cancer ability through epithelial-mesenchymal transition (EMT) pathway. European Journal of Medicinal Chemistry 237, pages 114325.
Crossref
Crossref
Bárbara Zanesco Moehlecke, Renan Oliveira de Melo, Daiana Renck, Victoria Aumann, Mathias André Kunde, Angélica Regina Cappellari, Paula Engroff & Fernanda Bueno Morrone. (2022) Impacto do tratamento oncológico na qualidade de vida de idosas com câncer de mama atendidas pelo Sistema Único de Saúde. PAJAR - Pan American Journal of Aging Research 10:1, pages e43014.
Crossref
Crossref
Charles N. Birts, Constantinos Savva, Stéphanie A. Laversin, Alicia Lefas, Jamie Krishnan, Aron Schapira, Margaret Ashton-Key, Max Crispin, Peter W. M. Johnson, Jeremy P. Blaydes, Ellen Copson, Ramsey I. Cutress & Stephen A. Beers. (2022) Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma. Scientific Reports 12:1.
Crossref
Crossref
Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang & Dennis J. Slamon. (2022) Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies. Molecular Cancer Therapeutics 21:5, pages 751-761.
Crossref
Crossref
Gregory A Vidal, Santosh Gautam, Anna Vlahiotis, Maxine D Fisher, Sonia Pulgar & Kendra DeBusk. (2022) Treatment patterns and overall survival in HER2+ metastatic breast cancer at US community oncology practices. Future Oncology 18:7, pages 849-858.
Crossref
Crossref
Rami Nassir & Ghada Esheba. (2022) Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer. Saudi Journal of Biological Sciences 29:3, pages 1808-1812.
Crossref
Crossref
G. Curigliano, V. Mueller, V. Borges, E. Hamilton, S. Hurvitz, S. Loi, R. Murthy, A. Okines, E. Paplomata, D. Cameron, L.A. Carey, K. Gelmon, G.N. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, J. Ramos, W. Feng & E. Winer. (2022) Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of Oncology 33:3, pages 321-329.
Crossref
Crossref
Wen Li, Qianqian Zhang, Yinlian Cai, Tingting Chen & Huaidong Cheng. (2022) The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2−/+ Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma & Binghe Xu. (2022) In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Frontiers in Oncology 11.
Crossref
Crossref
Jiyun Lee & Yeon Hee Park. (2022) Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncology 18:1, pages 7-19.
Crossref
Crossref
Tinslee Dilday & Elizabeth Yeh. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
11
34
.
Vladislav S. Rybchenko, Anna A. Panina, Teimur K. Aliev, Olga N. Solopova, Dmitry S. Balabashin, Valery N. Novoseletsky, Dmitry A. Dolgikh, Petr G. Sveshnikov & Mikhail P. Kirpichnikov. (2021) Bispecific Antibodies for IFN-β Delivery to ErbB2+ Tumors. Biomolecules 11:12, pages 1915.
Crossref
Crossref
Samer A. Naffouje, Arvind Sabesan, Susan J. Hoover, Marie C. Lee & Christine Laronga. (2021) Surgical Management of the Axilla of HER2+ Breast Cancer in the Z1071 Era: A Propensity-Score-Matched Analysis of the NCDB. Annals of Surgical Oncology 28:13, pages 8777-8788.
Crossref
Crossref
Andreia Borges, Filipa Pereira, Patrícia Redondo, Luís Antunes, Cláudia Vieira, Pedro Antunes, Maria José Bento, Susana Sousa, José Machado Lopes, Francisco Rocha-Gonçalves, Joaquim Abreu de Sousa, Deolinda Sousa Pereira & Marina Borges. (2021) The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data. Health Economics Review 11:1.
Crossref
Crossref
Jo-Ann Osei-Twum, Sahra Gedleh, Aisha Lofters & Onye Nnorom. (2021) Differences in Breast Cancer Presentation at Time of Diagnosis for Black and White Women in High Resource Settings. Journal of Immigrant and Minority Health 23:6, pages 1305-1342.
Crossref
Crossref
Vassiliki Rapti, Evangelia Moirogiorgou, Georgia-Angeliki Koliou, Kyriaki Papadopoulou, Ioannis Binas, George Pentheroudakis, Dimitrios Bafaloukos, Mattheos Bobos, Kyriakos Chatzopoulos, Sofia Chrisafi, Christos Christodoulou, Irene Nicolaou, Maria Sotiropoulou, Christina Magkou, Angelos Koutras, Pavlos Papakostas, Athanasios Kotsakis, Evangelia Razis, Amanda Psyrri, Dimitrios Tryfonopoulos, Dimitrios Pectasides, Eleni Res, Athanasios Alexopoulos, Vassiliki Kotoula & George Fountzilas. (2021) mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. Oncology Letters 23:1.
Crossref
Crossref
Gedmante Radziuviene, Allan Rasmusson, Renaldas Augulis, Ruta Barbora Grineviciute, Dovile Zilenaite, Aida Laurinaviciene, Valerijus Ostapenko & Arvydas Laurinavicius. (2021) Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. Frontiers in Oncology 11.
Crossref
Crossref
Kendra DeBusk, Shaun Abeysinghe, Adrian Vickers, Anubhav Nangia, Judith Bell, Chiemeka Ike, Andres Forero-Torres & Matthew T Blahna. (2021) Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncology 17:33, pages 4635-4647.
Crossref
Crossref
Marc Peeters, David Planchard, Mark Pegram, João Gonçalves, François Bocquet & Harah Jang. (2021) Biosimilars in an era of rising oncology treatment options. Future Oncology 17:29, pages 3881-3892.
Crossref
Crossref
Olga Martínez-Sáez & Aleix Prat. (2021) Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO Oncology Practice 17:10, pages 594-604.
Crossref
Crossref
Francesco Schettini & Aleix Prat. (2021) Dissecting the biological heterogeneity of HER2-positive breast cancer. The Breast 59, pages 339-350.
Crossref
Crossref
Chrystel Isca, Federico Piacentini, Ilenia Mastrolia, Valentina Masciale, Federica Caggia, Angela Toss, Claudia Piombino, Luca Moscetti, Monica Barbolini, Michela Maur, Massimo Dominici & Claudia Omarini. (2021) Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers 13:19, pages 4894.
Crossref
Crossref
Rosalynd UptonAllison BanuelosDongdong FengTanuka BiswasKevin Kao, Kelly McKennaStephen WillinghamPo Yi HoBenyamin Rosental, Michal Caspi Tal, Tal RavehJens-Peter VolkmerMark D. Pegram & Irving L. Weissman. (2021) Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences 118:29.
Crossref
Crossref
Jesse Sussell, Gurleen Singh Jhuti, Vincent Antao, Oscar Herrera-Restrepo, Elizabeth Wehler & S. Pinar Bilir. (2021) Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States. American Journal of Clinical Oncology 44:7, pages 340-349.
Crossref
Crossref
Amy Kwan, Natalie Winder & Munitta Muthana. (2021) Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances. Viruses 13:6, pages 1128.
Crossref
Crossref
Matthew K. Stein, Oluchukwu Oluoha, Kruti Patel & Ari VanderWalde. (2021) Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. Journal of Personalized Medicine 11:6, pages 518.
Crossref
Crossref
Christopher E. Eyermann, Jinyu Li & Evguenia M. Alexandrova. (2021) p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer. Cell Death & Disease 12:6.
Crossref
Crossref
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue’e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk & Qingyu Wang. (2021) Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. BioDrugs 35:3, pages 337-350.
Crossref
Crossref
J. Delgado, C. Vleminckx, S. Sarac, A. Sosa, J. Bergh, R. Giuliani, H. Enzmann & F. Pignatti. (2021) The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open 6:2, pages 100074.
Crossref
Crossref
Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde & Evandro de Azambuja. (2021) The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers 13:5, pages 1015.
Crossref
Crossref
M. K. Ramirez‐Fort, B. Meier‐Schiesser, K. Lachance, S. S. Mahase, C. D. Church, M. J. Niaz, H. Liu, V. Navarro, A. Nikolopoulou, D. V. Kazakov, E. Contassot, D. P. Nguyen, J. Sach, L. Hadravsky, Y. Sheng, S. T. Tagawa, X. Wu, C. S. Lange, L. E. French, P. T. Nghiem & N. H. Bander. (2020) Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma. Skin Health and Disease 1:1.
Crossref
Crossref
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido & Aleix Prat. (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer 7:1.
Crossref
Crossref
Shiva Niakan, Heather Love, Qing Cao & Nada Kawar. (2020) Primary invasive lobular carcinoma arising in mammary‐like glands of the vulva managed with neoadjuvant trastuzumab‐based chemotherapy, excision, and sentinel lymph node biopsy. Clinical Case Reports 9:1, pages 118-122.
Crossref
Crossref
Philip Bredin, Janice M. Walshe & Neelima Denduluri. (2020) Systemic therapy for metastatic HER2-positive breast cancer. Seminars in Oncology 47:5, pages 259-269.
Crossref
Crossref
Cristina Fortuno, Jessica Mester, Tina Pesaran, Jeffrey N. Weitzel, Jill Dolinsky, Amal Yussuf, Kelly McGoldrick, Judy E. Garber, Sharon A. Savage, Payal P. Khincha, D. Gareth Evans, Maria Isabel Achatz, Kim E. Nichols, Kara N. Maxwell, Joshua D. Schiffman, Renata Sandoval, Paul A. James & Amanda B. Spurdle. (2020)
Suggested application of HER2+ breast tumor phenotype for germline
TP53
variant classification within ACMG/AMP guidelines
. Human Mutation 41:9, pages 1555-1562.
Crossref
Crossref
Qiuji Wu, Weiting Liao, Mengxi Zhang, Jiaxing Huang, Pengfei Zhang & Qiu Li. (2020) Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives. Frontiers in Oncology 10.
Crossref
Crossref
Yakup ERGÜN, Nuriye YILDIRIM ÖZDEMİR, Ozan YAZICI, Gökhan UÇAR, Yusuf AÇIKGÖZ, Öznur BAL & Doğan UNCU. (2020) HER2-pozitif lokal ileri meme kanserinde neoadjuvan trastuzumab sıralamasının patolojik tam yanıt üzerine etkisi. Bozok Tıp Dergisi.
Crossref
Crossref
Astrid De Cuyper, Marc Van Den Eynde & Jean-Pascal Machiels. (2020) HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clinical Colorectal Cancer 19:2, pages 65-72.
Crossref
Crossref
Sandip Ganguly, Joydeep Ghosh, Bivas Biswas & Deepak Dabkara. (2021) Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Indian Journal of Medical and Paediatric Oncology 41:02, pages 218-220.
Crossref
Crossref
Francesco Schettini, Tomás Pascual, Benedetta Conte, Nuria Chic, Fara Brasó-Maristany, Patricia Galván, Olga Martínez, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Aranzazu Fernández-Martinez, Carla Rognoni, Gaia Griguolo, Valentina Guarneri, Pier Franco Conte, Mariavittoria Locci, Jan C. Brase, Blanca Gonzalez-Farre, Patricia Villagrasa, Sabino De Placido, Rachel Schiff, Jamunarani Veeraraghavan, Mothaffar F. Rimawi, C. Kent Osborne, Sonia Pernas, Charles M. Perou, Lisa A. Carey & Aleix Prat. (2020) HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews 84, pages 101965.
Crossref
Crossref
Rashmi K. MurthySherene LoiAlicia OkinesElisavet PaplomataErika HamiltonSara A. HurvitzNancy U. LinVirginia BorgesVandana AbramsonCarey AndersPhilippe L. BedardMafalda OliveiraErik JakobsenThomas BachelotShlomit S. ShacharVolkmar MüllerSofia BragaFrancois P. Duhoux, Richard GreilDavid CameronLisa A. CareyGiuseppe CuriglianoKaren GelmonGabriel HortobagyiIan KropSibylle LoiblMark PegramDennis SlamonM. Corinna Palanca-WesselsLuke WalkerWentao FengEric P. Winer. (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine 382:7, pages 597-609.
Crossref
Crossref
Amita Singh & Jeanne M. DeCara. (2020) The Current and Future Role of Echocardiography for the Detection of Cardiotoxicity Related to Cancer Therapy. Current Cardiovascular Imaging Reports 13:1.
Crossref
Crossref
Miriam Van den Nest, Anna Glechner, Maria Gold & Gerald Gartlehner. (2019) The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review. Systematic Reviews 8:1.
Crossref
Crossref
Naomi R.M. SchwartzMeghan R. FlanaganJoseph B. BabigumiraLotte M. SteutenJoshua A. Roth. (2019) Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1133-1139.
Crossref
Crossref
Peng ZhangXiaoke ZhangCheng LiSensen ZhouWei Wu & Xiqun Jiang. (2019) Target-Amplified Drug Delivery of Polymer Micelles Bearing Staudinger Ligation. ACS Applied Materials & Interfaces 11:36, pages 32697-32705.
Crossref
Crossref
Fredrika Schill, Margareta Nilsson, Daniel S Olsson, Oskar Ragnarsson, Katarina Berinder, Britt Edén Engström, Per Dahlqvist, Jeanette Wahlberg, Elisabet Englund & Pia Burman. (2019) Pituitary Metastases: A Nationwide Study on Current Characteristics With Special Reference to Breast Cancer. The Journal of Clinical Endocrinology & Metabolism 104:8, pages 3379-3388.
Crossref
Crossref
G. Travis Clifton, Kaitlin M. Peace, Jarrod P. Holmes, Timothy J. Vreeland, Diane F. Hale, Garth S. Herbert, Jennifer K. Litton, Rashmi K. Murthy, Jason Lukas, George E. Peoples & A. Mittendorf Elizabeth. (2019) Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clinical Immunology 201, pages 48-54.
Crossref
Crossref
Maryam Nakhjavani, Jennifer E Hardingham, Helen M Palethorpe, Yoko Tomita, Eric Smith, Tim J Price & Amanda R Townsend. (2019) Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer. Medicines 6:1, pages 17.
Crossref
Crossref
Chieh-Yu Lin, Eugene E Carneal, Daphne Y Lichtensztajn, Scarlett L Gomez, Christina A Clarke, Kristin C Jensen, Allison W Kurian & Kimberly H Allison. (2017) Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California. American Journal of Clinical Pathology 148:3, pages 199-207.
Crossref
Crossref
Brigid K. Killelea, Anees B. Chagpar, Nina R. Horowitz & Donald R. Lannin. (2017) Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011. The American Journal of Surgery 213:2, pages 426-432.
Crossref
Crossref
Suthat Chottanapund, M. Van Duursen, Kumpol Ratchaworapong, Panida Navasumrit, Mathuros Ruchirawat & Martin Van den Berg. (2016) Androgen Receptor Expression in Thai Breast Cancer Patients. Medical Sciences 4:3, pages 15.
Crossref
Crossref
Jasmeet Chadha Singh & Stuart M. Lichtman. (2015) Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs & Aging 32:12, pages 975-982.
Crossref
Crossref
Betsy A. Kohler, Recinda L. Sherman, Nadia Howlader, Ahmedin Jemal, A. Blythe Ryerson, Kevin A. Henry, Francis P. Boscoe, Kathleen A. Cronin, Andrew Lake, Anne-Michelle Noone, S. Jane Henley, Christie R. Eheman, Robert N. Anderson & Lynne Penberthy. (2015) Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. JNCI: Journal of the National Cancer Institute 107:6.
Crossref
Crossref
Raquel E. Reinbolt, Neha Mangini, Jordan L. Hill, Lauren B. Levine, Jessica L. Dempsey, Janani Singaravelu, Kevin A. Koehler, Allison Talley & Maryam B. Lustberg. (2015) Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars in Oncology Nursing 31:2, pages 146-155.
Crossref
Crossref
Nadia Howlader, Sean F. Altekruse, Christopher I. Li, Vivien W. Chen, Christina A. Clarke, Lynn A. G. Ries & Kathleen A. Cronin. (2014) US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI: Journal of the National Cancer Institute 106:5.
Crossref
Crossref
Rahber TharianiNorah Lynn Henry, Scott D Ramsey, David K Blough, Bill Barlow, Julie R Gralow & David L Veenstra. (2013) Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. Journal of Comparative Effectiveness Research 2:3, pages 325-334.
Crossref
Crossref
Asmerom Tesfamariam & Indrojit Roy. (2013) Molecular Biology of Breast Cancer in the Horn of Africa: Case Series—A Pilot Study of Breast Cancer from Eritrea. ISRN Pathology 2013, pages 1-7.
Crossref
Crossref
Roxana Schillaci, Pablo Guzmán, Florencia Cayrol, Wendy Beguelin, María C Díaz Flaqué, Cecilia J Proietti, Viviana Pineda, Jorge Palazzi, Isabel Frahm, Eduardo H Charreau, Esteban Maronna, Juan C Roa & Patricia V Elizalde. (2012) Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 12:1.
Crossref
Crossref
Jing Li, Bao-Ning Zhang, Jin-Hu Fan, Yi Pang, Pin Zhang, Shu-Lian Wang, Shan Zheng, Bin Zhang, Hong-Jian Yang, Xiao-Ming Xie, Zhong-Hua Tang, Hui Li, Jia-Yuan Li, Jian-Jun He & You-Lin Qiao. (2011) A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer 11:1.
Crossref
Crossref
Xiao-mei Yuan, Ning Wang, Tao Ouyang, Lei Yang, Ming-yang Song, Ben-yao Lin, Yun-tao Xie, Jin-feng Li, Kai-feng Pan, Wei-cheng You & Lian Zhang. (2011) Current status of diagnosis and treatment of primary breast cancer in Beijing, 2008. Chinese Journal of Cancer Research 23:1, pages 38-42.
Crossref
Crossref